The estimated Net Worth of David A Baldini is at least $7.6 ezer dollars as of 23 September 2004. David Baldini owns over 5,000 units of AIM ImmunoTech Inc stock worth over $7,597 and over the last 20 years David sold AIM stock worth over $0.
David has made over 1 trades of the AIM ImmunoTech Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently David bought 5,000 units of AIM stock worth $20,200 on 23 September 2004.
The largest trade David's ever made was buying 5,000 units of AIM ImmunoTech Inc stock on 23 September 2004 worth over $20,200. On average, David trades about 1,667 units every 0 days since 2004. As of 23 September 2004 David still owns at least 24,515 units of AIM ImmunoTech Inc stock.
You can see the complete history of David Baldini stock trades at the bottom of the page.
David's mailing address filed with the SEC is 595 GLENGARRY COURT, , EARLYSVILLE, VA, 22936.
Over the last 20 years, insiders at AIM ImmunoTech Inc have traded over $15,026,013 worth of AIM ImmunoTech Inc stock and bought 898,126 units worth $656,210 . The most active insiders traders include Thomas K Equels, J Mervyn Nabors és Commercial Bank First. On average, AIM ImmunoTech Inc executives and independent directors trade stock every 125 days with the average trade being worth of $16,943. The most recent stock trade was executed by Thomas K Equels on 6 May 2024, trading 61,729 units of AIM stock currently worth $25,309.
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
AIM ImmunoTech Inc executives and other stock owners filed with the SEC include: